Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending September 30, 2022 was 4.15 (a -64.3% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA decreased by -11314.32%
- Annual Net Debt/EBITDA for 2021 was 6.06 (a -142.65% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was -14.21 (a 207.86% increase from previous year)
- Annual Net Debt/EBITDA for 2019 was -4.62 (a 60.12% increase from previous year)
Visit stockrow.com/BBLG for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of Bone Biologics Corp.Most recent Net Debt/EBITDAof BBLG including historical data for past 10 years.
Interactive Chart of Net Debt/EBITDA of Bone Biologics Corp.
Bone Biologics Corp. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
Business Profile of Bone Biologics Corp.
Industry: Medical Devices